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Ketamine is an injectable anesthetic and recreational drug of abuse commonly used
worldwide. Many experimental studies have shown that ketamine can impair cognitive
function and induce psychotic states. Neuroinflammation has been suggested to play
an important role in neurodegeneration. Meanwhile, ketamine has been shown to
modulate the levels of inflammatory cytokines. We hypothesized that the effects of
ketamine on the central nervous system are associated with inflammatory cytokines.
Therefore, we set out to establish acute and chronic ketamine administration models
in C57BL/6 mice, to evaluate spatial recognition memory and emotional response,
to analyze the changes in the levels of the inflammatory cytokines interleukin-6 (IL-6),
interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) in the mouse hippocampus,
employing behavioral tests, Western blot, quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) and immunohistochemistry. Our results showed that ketamine
at the dose of 60 mg/kg induced spatial recognition memory deficit and reduced anxiety-
like behaviors in mice after chronic administration. Moreover, we found that ketamine
increased the hippocampal levels of IL-6 and IL-1β after single, multiple and long-term
administration in a dose-dependent manner. However, the expression level of TNF-α
differed in the mouse hippocampus under different conditions. Single administration of
ketamine increased the level of TNF-α, whereas multiple and long-term administration
decreased it significantly. We considered that TNF-α expression could be controlled by
a bi-directional regulatory pathway, which was associated with the dose and duration
of ketamine administration. Our results suggest that the alterations in the levels of
inflammatory cytokines IL-6, IL-1β, and TNF-α may be involved in the neurotoxicity of
ketamine.
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INTRODUCTION
Ketamine, derived from phencyclidine classes (N-1-
phenycyclohexypiperidine, PCP), acts as a non-competitive
N-methyl-D-aspartate (NMDA) receptor antagonist (Martin
and Lodge, 1985) by binding to the phencyclidine site (Orser
et al., 1997), and has been commonly used as a type of clinical
anesthetic since the 1960s (Haas and Harper, 1992). At low doses,
ketamine can produce a psychedelic experience of incredible
intensity (Strayer and Nelson, 2008). Because of these side
reactions, it has become increasingly popular in recent years as a
recreational drug (Lankenau et al., 2007). Experimental studies
have shown that ketamine, either acute or chronic, can induce
various cognitive impairments (Morgan et al., 2006; Chan et al.,
2013; Duan et al., 2013). The acute application of ketamine
gives rise to transient behavioral states in rats that mirror many
symptoms of schizophrenia, such as motor disturbances and
disturbed social behaviors (Becker et al., 2003; Razoux et al.,
2007). With regard to the long-term effects of ketamine, one study
found that mice exposed to a subanesthetic dose of ketamine
(30 mg/kg) for 6 months showed a hyperphosphorylation of tau
and apoptosis in the prefrontal and entorhinal cortex (Yeung
et al., 2010). Another study performed with developing monkeys
showed that prolonged exposure to ketamine increased cell death
in brain areas (Zou et al., 2009). These findings suggested that
acute and chronic ketamine administration may interfere with
the central nervous system.
Neuroinflammation has been suggested to be involved
in neurodegeneration. Inflammatory cytokines, including
interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis
factor-α (TNF-α), are cytokines involved in inflammation,
which could be released quickly under pathological conditions,
causing an inflammatory response in the central nervous system.
IL-6, IL-1β, and TNF-α have been reported to be associated
with learning and memory impairment (Reichenberg et al.,
2001; Sparkman et al., 2006). Ketamine has the potential
to modulate inflammation. A previous study showed that
ketamine exerted an anti-inflammatory effect in the presence
of inflammation, and recommended that it be used in the
surgery of sepsis patients due to its anti-inflammatory effects
(Takahashi et al., 2010). However, it was still unclear how
the levels of IL-6, IL-1β, and TNF-α would change in the
mouse hippocampus after short-term and long-term ketamine
administration. We therefore set out to establish acute and
chronic ketamine administration models in C57BL/6 mice at
a subanesthetic dose, to determine whether mice exhibited
changes in spatial memory and emotional response and to
investigate the alterations in mouse hippocampal levels of IL-6,
IL-1β, and TNF-α by applying the Y maze test, open field test,
Western blot, qRT-PCR, and immunohistochemistry. We tried
to determine the effects of short-term and long-term ketamine
administration on the levels of IL-6, IL-1β, and TNF-α in
mouse hippocampus, and to analyze the possible underlying
relationship between behavioral performances and the alterations
in the levels of IL-6, IL-1β, and TNF-α induced by ketamine,
to provide preliminary evidence regarding the neurotoxicity of
ketamine.
MATERIALS AND METHODS
Animals
Sixty 2-month-old (for chronic experiment) and one hundred
and twenty 3-month-old (for acute experiment) naive adult
male C57BL/6 mice from Laboratory Animal Centre of China
Medical University, weighing 22–28 g, were housed four per
cage and maintained on a 12-h light/dark cycle (lights out at
5:00 PM). Mice had unlimited access to water and food in
their home cages. All animal use procedures were in accordance
with the Regulations of Experimental Animal Administration
issued by the State Committee of Science and Technology of
the People’s Republic of China and the Guidelines of the Care
and Use of Laboratory Animals of China Medical University.
The experimental techniques were approved by the Institutional
Animal Care and Use Committee of China Medical University.
All efforts were made to minimize the number of animals used
and to reduce their suffering.
Ketamine Administration
Ketamine hydrochloride (Fujian Gutian Pharmaceutical Co.,
Ltd, Gutian, Fujian, China), was dissolved in physiological
saline.
In the acute experiment, we gave mice a single intraperitoneal
(i.p.) injection of ketamine or multiple (six times) consecutive
i.p. injections of ketamine at 1-h intervals, based on the methods
described in previous studies (Huang et al., 2015, 2016), with
modifications. For both single and multiple administrations,
mice were randomly assigned to five groups, with 12 mice
per group: saline-treated group, 10 mg/kg ketamine group,
20 mg/kg ketamine group, 40 mg/kg ketamine group, and
80 mg/kg ketamine group. Animals received i.p. injection of
ketamine or equal volume of physiological saline according
to group, for a single time injection or six times consecutive
injections at 1-h intervals. After behavioral tests, all mice
of each group were used for proteomic and transcriptomic
analysis.
In the chronic experiment, we gave mice a 6-month
course of daily i.p. injection of ketamine, as described in
previous studies (Yeung et al., 2010; Sun et al., 2011).
Mice were randomly assigned to three groups, with 20
mice per group: saline-treated group, 30 mg/kg ketamine
group and 60 mg/kg ketamine group. Animals received i.p.
injection of ketamine or equal volume of physiological saline
according to group for 6 months. The body weights of
mice were recorded every week for adjustment of ketamine
administration. After behavioral tests, 10 mice of each group
were randomly selected for immunohistochemical staining, and
the other 10 mice used for proteomic and transcriptomic
analysis.
We used subanesthetic doses of 30 and 60 mg/kg for
chronic administration and 10, 20, 40, and 80 mg/kg for acute
administration, which were based on the doses reported in
previous studies (Hunt et al., 2006; Enomoto and Floresco, 2009;
Wang et al., 2011, 2014), with modifications. All mice were
sacrificed by cervical dislocation 6 h after the last i.p. injection.
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Behavioral Tests
All behavioral tests were performed 3 h after the last i.p. injection.
All mice were in a normal state before and during the behavior
acquisition. All procedures were performed during the light
period. Mice that exhibited passivity were excluded from analysis.
Open Field Test
We used the open field test to evaluate anxiety-like response after
ketamine administration, as previously described (Akillioglu
et al., 2012). The open field apparatus was a four-walled
black plastic box that measured 40 cm × 40 cm × 30 cm
(length/width/height) with a white bottom and no top. The
squares adjacent to the wall were designated as “peripheral,”
while the others were designated as “central” (23 cm × 23 cm).
Peripheral fields were safe and protected, whereas the central
fields were unprotected in the open field apparatus. For the
open field test, mice were placed in a corner of the apparatus.
All environments were thoroughly cleaned with 70% ethanol
between trials. Behavioral performances were recorded for
10 min using a video camera. SMARTTM tracking software
program (San Diego Instruments, San Diego, CA, USA) was used
to calculate the time spent in the center of the open field.
Y Maze Test
We used the Y maze test to measure spatial recognition memory,
as previously described (Dellu et al., 2000; Ma et al., 2007). The
Y maze apparatus consisted of three arms with an angle of 120◦
between each two arms. Each arm of the maze was 30 cm long,
15 cm high, and 6 cm wide, and converged at an equal angle. The
three identical arms were randomly designated as follows: initial
arm, in which the mouse started to explore; novel arm, which
was blocked during the first trial, but open during the second
trial; and familiar arm. Visual cues were placed on the walls of
the mazes. The Y maze test consisted of two trials separated
by 2-h intervals to assess spatial recognition memory. The first
trial (training) lasted 8 min and allowed mice to explore only
the initial arm and familiar arm of the maze, with the novel
arm being blocked. After 2-h intervals, the second trial was
conducted for 2 min, during which all three arms were accessible.
All environments were thoroughly cleaned with 70% ethanol
between trials. This test is based on the interest of mice for
novelty, hence they explore preferentially unknown territories.
Behavioral performances were recorded using a video camera.
SMARTTM tracking software program (San Diego Instruments,
San Diego, CA, USA) was used to calculate the time spent in the
novel arm.
Western Blot Assay
Western blot analysis was used to determine the protein
levels of IL-6, IL-1β, and TNF-α as previously described (Lu
et al., 2010), with modifications. Briefly, mice were sacrificed
by cervical dislocation, and the hippocampus was dissected
out. Hippocampal cytosol proteins were extracted using the
Membrane and Cytosol Protein Extraction Kit (P0033, Beyotime,
Shanghai, China) and quantified for total protein with the BCA
Protein Assay Kit (P0012, Beyotime, Shanghai, China). Next,
20 µg of protein of each lysate were separated by SDS-PAGE
and the bands transferred to PVDF membranes. After being
blocked with 4% bovine serum albumin in Tris-buffered saline-
Tween-20 at room temperature for 2 h, the membranes were
incubated, respectively, with anti-IL-6 (1:2000, 21865-1-AP,
Proteintech), anti-IL-1β (1:2000, 16765-1-AP, Proteintech), anti-
TNF-α (1:2000, ab9739, Abcam), or anti-β-actin (1:5000, ab8226,
Abcam) overnight at 4◦C. After washing, the membranes were
incubated with appropriate horseradish peroxidase-conjugated
secondary antibodies (1:5000, ZSGB-BIO, Beijing, China) at
room temperature for 2 h. The blots were visualized with
luminal reagent, and images were taken and analyzed by
Electrophoresis Gel Imaging Analysis System (Tanon 5500,
Shanghai, China).
Immunohistochemistry Assay
Mice were fully anesthetized with chloral hydrate (400 mg/kg,
i.p.) and then transcardially perfused with phosphate-buffered
saline (PBS) (pH 7.4) followed by 4% paraformaldehyde
dissolved in 0.1 M phosphate buffer (pH 7.4). The brain was
then removed from the skull and fixed at 4◦C overnight in
4% paraformaldehyde. The hippocampus was embedded with
paraffin and then sectioned coronally at a thickness of 5 µm.
For immunohistochemical staining, deparaffinized sections were
heated for 5 min in 0.01 M sodium citrate buffer (pH 6.0) for
antigen retrieval. Endogenous peroxide activity was quenched
with 3% hydrogen peroxide, and non-specific binding was
blocked with non-immune serum. The sections were then
incubated, respectively, with anti- IL-6 (1:300, 21865-1-AP,
Proteintech), anti-IL-1β (1:300, 16765-1-AP, Proteintech), anti-
TNF-α (1:300, ab9739, Abcam) at 4◦C overnight, and followed
by incubation with appropriate biotinylated secondary antibody
in SPlink Detection Kit (ZSGB-BIO, Beijing, China) for 1 h
at 37◦C. The immunostaining positive cells in the mouse
hippocampus were detected using a light microscope (Olympus
BX 41, Japan). Images were captured. The relative expression
levels of IL-6, IL-1β, and TNF-α were quantified by the mean
optical density (MOD) value. Measurements were performed
as follows: integrated optical density (IOD) and total stained
area (S) in each image were recorded using the Image-Pro
Plus 6.0 software (Media Cybernetics, Rockville, MD, USA).
MOD = IOD/S, equivalent to the intensity of stain in all positive
cells.
Quantitative Reverse
Transcriptase-Polymerase Chain
Reaction (qRT-PCR)
The qRT-PCR method was performed as previously described
(Wu et al., 2012) with modifications, not following the MIQE
guidelines. Briefly, total RNA was isolated with TRIzol according
to the manufacturer’s instructions. RNA was reversely transcribed
into complementary deoxyribonucleic acid (cDNA) using
PrimeScriptTM RT Reagent Kit (RR037A, Takara Biotechnology,
Shiga, Japan). RNA concentration was determined using a
NanoDrop ND-1000 Spectrophotometer (Thermo Fisher
Scientific, Wilmington, DE, USA). Real-time PCR amplification
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was carried out by Applied Biosystems 7500 Real-time PCR
System using the SYBR R© PrimeScriptTM RT-PCR Kit (RR820A,
Takara Biotechnology, Shiga, Japan). IL-6, IL-1β, and TNF-α
mRNA levels were determined and standardized with mouse
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as
internal control. No significant changes in GAPDH mRNA levels
were observed. Primer sequences were as follows: IL-6, forward:
5′- CAAAGCCAGAGTCCTTCAGAG -3′, reverse: 5′- GTCCT
TAGCCACTCCTTCTG -3′; IL-1β, forward: 5′- ACGGACCCC
AAAAGATGAAG -3′, reverse: 5′- TTCTCCACAGCCACAAT
GAG -3′; TNF-α, forward: 5′- CTTCTGTCTACTGAACTTC
GGG -3′, reverse: 5′- CAGGCTTGTCACTCGAATTTTG -3′;
and GAPDH, forward: 5′- CTTTGTCAAGCTCATTTCCTGG
-3′, reverse: 5′- TCTTGCTCAGTGTCCTTGC -3′. To exclude
any potential contamination, negative controls were also
performed with dH2O instead of cDNA during each run, and
no amplification product was detected. The real-time PCR
procedure was repeated at least three times for each sample.
Relative quantification method was used to calculate the
difference in gene expression (Livak and Schmittgen, 2001). The
data were presented as fold changes in target gene expression
normalized to GAPDH.
Statistical Analysis
One-way analysis of variance (ANOVA) followed by the
least significant difference (LSD) t-test was used to compare
differences between groups. These statistical analyses were
conducted by Statistical Product for Social Sciences (SPSS version
13.0). p-values less than 0.05 (∗ or #) and 0.01 (∗∗ or ##) were
considered statistically significant.
RESULTS
Open Field Test
In the chronic experiment, mice that received 6 months of
daily administration of 60 mg/kg ketamine significantly spent
more time in the center of the open field compared to the
saline-treated group [Figure 1A; F(2,33) = 3.973, p = 0.028],
but not the 30 mg/kg group. No significant differences were
observed between 60 and 30 mg/kg ketamine groups after long-
term administration. Total distance moved in the open field
was not significantly affected by chronic ketamine administration
[Figure 1B; F(2,33) = 0.104, p = 0.902]. In the acute experiment,
our results showed that ketamine at all doses (10, 20, 40, and
80 mg/kg), whether with single [Figure 1C; F(4,55) = 1.025,
p = 0.403] or multiple [Figure 1C; F(4,55) = 0.836, p = 0.508]
administration, did not induce any significant differences in the
time spent in the center of the open field compared to the saline-
treated group. The data from the open field test indicated that
ketamine treatment at 60 mg/kg for 6 months reduced anxiety-
like behaviors in mice, whereas acute administration had no
effect.
Y Maze Test
We used the Y maze test to determine the effects of
ketamine administration on spatial recognition memory. Results
showed that mice that received 6 months of daily ketamine
administration at a dose of 60 mg/kg exhibited a significant
reduction in the percentage of time spent in the novel arm with
respect to the total duration of visits in the three arms of Y maze
compared to the saline-treated group [Figure 1D; F(2,33) = 3.616,
FIGURE 1 | Effects of acute and chronic intraperitoneal injection of ketamine on anxiety-like behaviors in the open field test and spatial recognition
memory in the Y maze test. (A) Time spent in center of the open field (chronic). (B) Total distance moved in the open field (chronic). (C) Acute effects of ketamine
in the open field test. (D) The percentage of time spent in the novel arm with respect to the total duration of visits in the three arms of the Y maze (chronic). (E) Total
distance moved in the Y maze (chronic). (F) Acute effects of ketamine in the Y maze test. Data are expressed as mean ± SD, n = 12 for each group. Statistical
analysis used ANOVA to compare the difference between groups (∗p < 0.05).
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p= 0.038] but not the 30 mg/kg group. No significant differences
were observed between the 60 and 30 mg/kg ketamine groups
after long-term ketamine administration. Total distance moved
in the Y maze was not significantly affected by chronic ketamine
administration [Figure 1E; F(2,33) = 0.129, p = 0.879]. Similar
to the open field test results, no significant differences were
observed between the saline-treated group and each ketamine-
treated group (10, 20, 40, and 80 mg/kg) after acute ketamine
administration, whether with single [Figure 1F; F(4,55) = 1.892,
p = 0.125] or multiple [Figure 1F; F(4,55) = 2.021, p = 0.104]
administration. The Y maze test results indicated a spatial
recognition memory deficit with the 6-month administration
paradigm for 60 mg/kg ketamine, whereas acute ketamine
administration had no effect.
Single Administration of Ketamine
Increased the Protein Levels of IL-6,
IL-1β, and TNF-α in Mouse Hippocampus
6 h after Injection
Inflammatory cytokines, including IL-6, IL-1β, and TNF-α, have
been reported to be associated with learning and memory
impairment. Therefore, we determined the hippocampal cytosol
protein levels of IL-6, IL-1β, and TNF-α. Our Western blot
results revealed that only the single administration of 80 mg/kg
ketamine significantly increased IL-6 level normalized to β-actin
as compared with the saline-treated group [Figures 2A,B;
F(4,55) = 9.17, p < 0.001]. Lower doses of ketamine (10, 20,
and 40 mg/kg) did not induce an evident increase in IL-6
FIGURE 2 | Single intraperitoneal injection of ketamine increased the protein levels of IL-6, IL-1β, and TNF-α in mouse hippocampus as compared
with saline-treated group 6 h after administration. (A) Effects of single intraperitoneal injection of ketamine on IL-6, IL-1β, and TNF-α levels. (B) Quantification of
the Western blot shows that only the single intraperitoneal injection of 80 mg/kg ketamine significantly increased IL-6 level normalized to β-actin as compared with
saline-treated group. (C) Quantification of the Western blot shows that all doses of single intraperitoneal injection of ketamine significantly increased IL-1β level
normalized to β-actin as compared with saline-treated group. (D) Quantification of the Western blot shows that all doses of single intraperitoneal injection of
ketamine significantly increased TNF-α level normalized to β-actin as compared with saline-treated group. Data are expressed as mean ± SD, n = 12 for each
group. Statistical analysis used ANOVA to compare the difference between saline-treated group and each ketamine-treated group (∗p < 0.05; ∗∗p < 0.01) and the
differences between ketamine-treated groups (#p < 0.05; ##p < 0.01).
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level. Moreover, the 80 mg/kg ketamine group displayed a
markedly higher level of IL-6 compared to the other ketamine
administration groups (10, 20, and 40 mg/kg) [Figure 2B;
#p < 0.05, ##p < 0.01]. Somewhat differently, all ketamine doses
(10, 20, 40, and 80 mg/kg) produced a significant increase in
IL-1β [Figures 2A,C; F(4,55) = 3.728, p = 0.009] and TNF-α
levels [Figures 2A,D; F(4,55) = 4.475, p = 0.003]. Meanwhile,
the 40 and 80 mg/kg ketamine groups exhibited a markedly
higher level of TNF-α compared to the 10 mg/kg ketamine group
[Figure 2D; #p < 0.05, ##p < 0.01]. These results indicated that
single administration of ketamine increased the protein levels of
IL-6 (only at the high dose of 80 mg/kg), IL-1β and TNF-α in
mouse hippocampus, but that low doses of ketamine (10, 20, and
40 mg/kg) had no effect on the level of IL-6.
Multiple (Six Times) Consecutive
Administration of Ketamine at 1-h
Intervals Increased the Protein Levels of
IL-6 and IL-1β, but Decreased the Protein
Levels of TNF-α in Mouse Hippocampus
6 h after the Last Injection
We further investigated hippocampal cytosol protein levels
of IL-6, IL-1β, and TNF-α after six times consecutive
administration. Similarly, Our Western blot results revealed
that only 80 mg/kg ketamine significantly increased IL-6 level
as compared with the saline-treated group [Figures 3A,B;
F(4,55) = 3.737, p = 0.009]. Lower doses of ketamine (10, 20,
and 40 mg/kg) did not induce a significant increase in IL-6
FIGURE 3 | Multiple (six times) consecutive intraperitoneal injection of ketamine at 1-h intervals increased the protein levels of IL-6 and IL-1β but
decreased the protein levels of TNF-α in mouse hippocampus as compared with saline-treated group 6 h after the last injection. (A) Effects of six times
consecutive intraperitoneal injection of ketamine at 1-h intervals on IL-6, IL-1β, and TNF-α levels. (B) Quantification of Western blot shows that six times consecutive
intraperitoneal injection of ketamine at 1-h intervals at only 80 mg/kg significantly increased IL-6 level normalized to β-actin as compared with saline-treated group.
(C) Quantification of Western blot shows that six times consecutive intraperitoneal injection of ketamine at 1-h intervals at the doses of 20, 40, and 80 mg/kg
significantly increased IL-1β level normalized to β-actin as compared with saline-treated group. (D) Quantification of Western blot shows that the six times
consecutive intraperitoneal injection of ketamine at 1-h intervals at the doses of 20, 40, and 80 mg/kg significantly decreased TNF-α level normalized to β-actin as
compared with saline-treated group. Data are expressed as mean ± SD, n = 12 for each group. Statistical analysis used ANOVA to compare the difference between
saline-treated group and each ketamine-treated group (∗p < 0.05; ∗∗p < 0.01) and the differences between ketamine-treated groups (#p < 0.05; ##p < 0.01).
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level. Moreover, the 80 mg/kg ketamine group displayed a
markedly higher IL-6 level compared to the 10, 20, and 40 mg/kg
ketamine groups [Figure 3B; #p < 0.05, ##p < 0.01]. The six
times consecutive administration of ketamine at 1-h intervals at
doses of 20, 40, and 80 mg/kg significantly increased IL-1β level
as compared with the saline-treated group but not the 10 mg/kg
ketamine group [Figures 3A,C; F(4,55) = 6.347, p < 0.001].
However, it is noteworthy that TNF-α level significantly
decreased after the six times consecutive administration of
ketamine at 1-h intervals at doses of 20, 40, and 80 mg/kg (not
10 mg/kg) as compared with saline-treated group [Figures 3A,D;
F(4,55) = 23.77, p < 0.001]. Moreover, the 20, 40, and 80 mg/kg
ketamine groups displayed a markedly lower level of TNF-
α compared to the 10 mg/kg ketamine group [Figure 3D;
#p < 0.05, ##p < 0.01]. These findings suggest that multiple (six
times) administration of ketamine increased the protein level of
IL-6 (only at the high dose of 80 mg/kg) and IL-1β (at doses of
20, 40, and 80 mg/kg) but decreased the protein level of TNF-α
(at doses of 20, 40, and 80 mg/kg) in mouse hippocampus.
Effects of Chronic (6 Months Daily)
Administration of 30 and 60 mg/kg
Ketamine on the Protein Levels and
Immunoreactivity Levels of IL-6, IL-1β,
and TNF-α
The chronic effects of ketamine on inflammatory cytokines
were investigated, where we determined the hippocampal
immunoreactivity levels and the hippocampal cytosol protein
levels of IL-6, IL-1β, and TNF-α after long-term (6 months
daily) administration of ketamine at the doses of 30 and
60 mg/kg. Like the results for multiple (six times) consecutive
injections, 6 months daily ketamine administration of 30
and 60 mg/kg increased the protein level [Figures 4A,B;
F(2,27) = 3.948, p = 0.031] and immunostaining level of IL-
6 (at dose of 60 mg/kg) [Figures 4C–F; F(2,15) = 4.313,
p = 0.033], the protein level [Figures 5A,B; F(2,27) = 6.782,
p = 0.004] and immunostaining level of IL-1β [Figures 5C–F;
F(2,15)= 4.732, p= 0.026] but decreased the protein level of TNF-
α [Figures 6A,B; F(2,27) = 9.012, p= 0.001] and immunostaining
level of TNF-α [Figures 6C–F; F(2,15) = 19.1, p < 0.001] in
mouse hippocampus. No significant differences were observed
between the 60 and 30 mg/kg ketamine groups after long-
term administration. These results suggest that ketamine may
increase the levels of IL-6 and IL-1β but may decrease
the level of TNF-α in mouse hippocampus after long-term
administration.
Effects of Acute and Chronic Ketamine
Administration on the mRNA Levels of
IL-6, IL-1β, and TNF-α
The changes in IL-6, IL-1β, and TNF-α levels after ketamine
administration could have been due to the changes in synthesis
or degradation. We therefore assessed the effects of ketamine
administration on the mRNA levels of IL-6, IL-1β, and TNF-
α. Our results showed that 6 months daily administration of
30 and 60 mg/kg ketamine increased the mRNA levels of IL-6
[Figure 7A; F(2,12) = 3.92, p = 0.048] and IL-1β [Figure 7B;
F(2,12) = 4.199, p = 0.042], but decreased the mRNA levels of
TNF-α [Figure 7C; F(2,12) = 8.984, p = 0.004] as compared with
the saline-treated group, using GAPDH as an internal control.
In acute experiment, ketamine significantly increased the mRNA
levels of IL-6 (at dose of 80 mg/kg) [Figure 7D; F(4,20) = 4.895,
p = 0.007], IL-1β (at doses of 20, 40, and 80 mg/kg) [Figure 7E;
F(4,20) = 2.944, p = 0.046] and TNF-α (at all doses) [Figure 7F;
F(4,20) = 2.907, p = 0.047] after single administration. Similarly,
ketamine also significantly increased the mRNA levels of IL-6 (at
dose of 80 mg/kg) [Figure 7G; F(4,20) = 2.932, p = 0.046], IL-1β
(at doses of 20, 40, and 80 mg/kg) [Figure 7H; F(4,20) = 5.809,
p = 0.003] and TNF-α (at all doses) [Figure 7I; F(4,20) = 2.901,
p = 0.048] after multiple administration. These results revealed
that ketamine may affect IL-6, IL-1β, and TNF-α expression levels
in mouse hippocampus at the transcription level.
DISCUSSION
In the present study, our findings indicate that hippocampal
inflammatory cytokines IL-6, IL-1β, and TNF-α may be involved
in the subanesthetic ketamine-induced behavioral changes in
mice.
The Y maze task is a specific and sensitive test of
spatial recognition memory in rodents (Dellu et al., 2000).
A large number of studies have shown that long-term
ketamine administration markedly induces learning and memory
impairment in humans (Morgan et al., 2004; Chan et al., 2013)
and mice (Tan et al., 2011). In our study, we used the Y maze
test to measure spatial recognition memory, and found that
only the mice that received chronic ketamine administration at
60 mg/kg (not 30 mg/kg) exhibited spatial memory deficit. This
was supported by a study in which mice exposed to 30 mg/kg
ketamine for 6 months showed no apparent deficit in learning
and memory (Sun et al., 2011), and another study in which rats
exhibited learning and memory impairment when exposed to
ketamine at 80 mg/kg but not at a lower dose of 30 mg/kg in
a 7 days administration paradigm (Wang et al., 2014). Previous
works by our research group showed that a higher dose of
ketamine (60 mg/kg) resulted in significant spatial learning and
memory impairment after 6 months administration, while lower
dose of ketamine (30 mg/kg) did not induce any apparent deficits
in Morris water maze tests and radial arm maze test (Ding et al.,
2016). These results indicate that cognitive function impairments
after chronic ketamine administration are dose-dependent in
mice. A previous study reported that a single i.p. injection of
ketamine at subanesthetic and anesthetic doses did not impair
recognition memory or reference memory and did not cause
neurodegeneration in adult mice (Ribeiro et al., 2013). Similarly,
we did not observe a significant difference between the saline-
treated group and each ketamine-treated group (10, 20, 40, or
80 mg/kg) after acute administration, whether with single or
multiple administration. We can conclude that acute ketamine
administration has no effect on spatial recognition memory in
mice.
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FIGURE 4 | Chronic (6 months daily) intraperitoneal injection of ketamine at 30 and 60 mg/kg increased the protein level and the immunostaining
level of IL-6. (A) Six months intraperitoneal injection of ketamine increased the protein level of IL-6. (B) Quantification of Western blot shows that 6 months
intraperitoneal injection of ketamine significantly increased IL-6 level normalized to β-actin as compared with saline-treated group. (C) Quantification of the
immunohistochemistry image shows that the ketamine administration at the 60 mg/kg significantly increased the IL-6 immunostaining level in mouse hippocampus.
(D–F) Immunohistochemistry studies show that the ketamine administration increased the IL-6 immunostaining level in mouse hippocampus. Scale bar = 100 µm.
Data are expressed as mean ± SD, n = 10 of each group for proteomic analysis and n = 6 of each group for immunohistochemical staining. Statistical analysis used
ANOVA to compare the difference between saline-treated group and each ketamine-treated group (∗p < 0.05).
In the open field test, our results showed that chronic
ketamine administration at high dose had a significant anxiolytic
effect. Mice displayed reduced anxiety-like behaviors after long-
term administration at the dose of 60 mg/kg, while low dose
ketamine (30 mg/kg) had no effect. Moreover, we did not observe
significant differences after acute ketamine administration,
whether with single or multiple administration. The results of
previous studies investigating the anxiety-related acute effects of
ketamine were completely different, with reports of anxiolytic
(Imre et al., 2006; Engin et al., 2009), anxiogenic (da Silva et al.,
2010; Akillioglu et al., 2012), and null (Sobota et al., 2015)
results. Some of the conclusions were inconsistent with our
results. The reason may be due to the fact that we performed
the behavioral tests 3 h after the last injection of ketamine or
saline, whereas the above-mentioned studies involved a much
shorter period (15–90 min) after ketamine injection. Ketamine
has a short half-life, and its metabolites are quickly cleared by
urinary excretion (Sinner and Graf, 2008). In our study, we aimed
to determine the stable and persistent effects of ketamine on the
mouse central nervous system rather than its immediate effect.
The acute application of ketamine may just give rise to transient
behavioral states, so behavioral tests performed a long time (such
as 3 h) after acute administration of ketamine may not show
effects on emotional response and cognitive function in mice.
Neuroinflammation has been suggested to play an important
role in neurodegeneration (Heneka and O’Banion, 2007;
Cameron and Landreth, 2010), and to cause cognitive
impairment both in humans (Hoogman et al., 2007) and
animals (Langdon et al., 2008). There is extensive evidence
that IL-6, as a proinflammatory cytokine, may affect brain
function and may be involved in pathological neurodegenerative
disorders. Studies have reported a positive association between
plasma IL-6 level and impairment in a wide range of cognitive
domains in humans (Gimeno et al., 2008; Simpson et al.,
2013; Heringa et al., 2014). Meanwhile, IL-6 overexpression in
the brain of transgenic mice has been shown to cause severe
neurological disease (Heyser et al., 1997). IL-6 knockout mice
have been found to exhibit better and faster acquisition in
learning and memory processes, demonstrating a facilitation
of spatial learning using the radial arm maze test (Braida
et al., 2004). With regard to IL-1β, it is required for normal
learning and memory processes, but exogenous administration
or excessive endogenous levels may produce detrimental
cognitive behavioral effects (Chen et al., 2008). A previous
study demonstrated a synergistic interaction between IL-1β
and other cytokines, causing enhanced cognitive dysfunction
(Allan et al., 2005). Another recent study confirmed that
IL-1β is involved in cognitive impairment after sepsis in
rats (Mina et al., 2014), showing that IL-1β may be involved
in brain dysfunction. TNF-α has been proven to play an
important role in central nervous system development and
functions including neuronal plasticity, cognition, and behavior
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FIGURE 5 | Chronic (6 months daily) intraperitoneal injection of ketamine at 30 and 60 mg/kg increased the protein level and the immunostaining
level of IL-1β. (A) Six months intraperitoneal injection of ketamine increased the protein level of IL-1β. (B) Quantification of Western blot shows that 6 months
intraperitoneal injection of ketamine significantly increased IL-1β level normalized to β-actin as compared with saline-treated group. (C) Quantification of the
immunohistochemistry image shows that the ketamine administration at 30 and 60 mg/kg significantly increased the IL-1β immunostaining level in mouse
hippocampus. (D–F) Immunohistochemistry studies show that the ketamine administration increased the IL-1β immunostaining level in mouse hippocampus. Scale
bar = 100 µm. Data are expressed as mean ± SD, n = 10 of each group for proteomic analysis and n = 6 of each group for immunohistochemical staining.
Statistical analysis used ANOVA to compare the difference between saline-treated group and each ketamine-treated group (∗p < 0.05; ∗∗p < 0.01).
(Garay and McAllister, 2010), where the disruption of TNF-α
signaling leads to abnormal development of the hippocampus
and impairments in cognitive function (Baune et al., 2012).
TNF-α was initially described as a cell death inducer, and as
a proinflammatory cytokine, it is generally recognized as a
worsening factor in the pathology of psychiatric disorders.
Several studies have suggested a link between increased TNF-α
levels and cognitive alteration (Yirmiya and Goshen, 2011;
Swardfager and Black, 2013), and a recent study showed that
local increase of TNF-α in the hippocampal dentate gyrus
activated astrocyte TNF receptor type 1 (TNFR1), which in turn
triggered an astrocyte-neuron signaling cascade that resulted
in persistent functional modification of hippocampal excitatory
synapses (Habbas et al., 2015). On the other hand, TNF-α has
also been suggested to have neuroprotective effects against cell
death induced by various neurotoxic insults (Orellana et al.,
2007; Rojo et al., 2008). Recent studies showed that decreased
serum TNF-α level in chronic schizophrenia patients was
significantly negatively correlated with psychopathological
symptoms (Lv et al., 2015). Collectively, there is a positive
association between IL-6 and IL-1β levels and impairment
in brain function. On the other hand, TNF-α seems to
have a more complex functionary mechanism, where it
plays a dual role in producing either neurodegeneration or
neuroprotection in the central nervous system (Orellana et al.,
2007).
Ketamine has been shown to modulate the inflammatory
response. Previous studies showed that ketamine had an
anti-inflammatory effect under inflammation conditions and
therefore recommended it for use in the surgery of sepsis
patients (Takahashi et al., 2010; Ward et al., 2011). In a chronic
stress-induced depression model, 10 mg/kg ketamine injection
showed a rapid antidepressant effect and effectively reduced
the protein expression levels of IL-6, IL-1β, and TNF-α (Wang
et al., 2015). In a septic rat model, low dose ketamine (0.5
and 5 mg/kg) had an anti-inflammatory effect, but high dose
ketamine (50 mg/kg) induced the expression of inflammatory
cytokines (Sun et al., 2004). In primary cortical cultures, a
sustained increase in IL-6 and a slight decrease in TNF-α
were observed during ketamine (0.5 µM) exposure in vitro
(Behrens et al., 2008). Another experiment in vitro found that
in the presence of lipopolysaccharide (LPS), treatment with
100 µM ketamine for 30 min significantly increased IL-6 and
TNF-α levels (Meng et al., 2015). These findings suggest a close
relationship between ketamine and the inflammatory cytokines
IL-6, IL-1β, and TNF-α; moreover, ketamine may have different
regulatory effects on inflammatory cytokines under different
conditions.
Our present study differed from previous investigations
using the animal models induced by stress, LPS or sepsis,
where we directly determined hippocampal cytosol protein
levels of IL-6, IL-1β, and TNF-α by using acute and chronic
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FIGURE 6 | Chronic (6 months daily) intraperitoneal injection of ketamine at 30 and 60 mg/kg decreased the protein level and the immunostaining
level of TNF-α. (A) Six months intraperitoneal injection of ketamine decreased the protein level of TNF-α. (B) Quantification of Western blot shows that 6 months
intraperitoneal injection of ketamine significantly decreased TNF-α level normalized to β-actin as compared with saline-treated group. (C) Quantification of the
immunohistochemistry image shows that the ketamine administration at 30 and 60 mg/kg significantly decreased the TNF-α immunostaining level in mouse
hippocampus. (D–F) Immunohistochemistry studies show that the ketamine administration decreased the TNF-α immunostaining level in mouse hippocampus.
Scale bar = 100 µm. Data are expressed as mean ± SD, n = 10 of each group for proteomic analysis and n = 6 of each group for immunohistochemical staining.
Statistical analysis used ANOVA to compare the difference between saline-treated group and each ketamine-treated group (∗∗p < 0.01).
ketamine administration models. We found that single ketamine
administration increased the protein levels of IL-6 (only at
the dose of 80 mg/kg), IL-1β, and TNF-α; multiple and
long-term administration of ketamine increased the protein
levels of IL-6 (only at 80 mg/kg when subjected to multiple
injection) and IL-1β but significantly decreased the protein
level of TNF-α in mouse hippocampus. These results indicate
that the effects of ketamine on the levels of IL-6 and
TNF-α are dose-dependent. Most importantly, the effects of
ketamine administration on the level of TNF-α may be
diametrically opposite under different conditions, depending
on the dose and duration of administration. A sustained
and repetitive stimulation could decrease the TNF-α level,
whereas single administration produced different results. Our
inference is well supported by a recent study in which the
authors measured serum TNF-α, IL-6, and IL-18 levels in
the 155 chronic ketamine abusers and 80 healthy control
subjects, and observed increased protein expression levels
of IL-6 and IL-18, whereas a significant decreased protein
expression level of TNF-α (Fan et al., 2015). As we mentioned
above, TNF-α may play a dual role in promoting either
neurodegeneration or neuroprotection in the central nervous
system; it seems that the effects of TNF-α on brain function
may be inconsistent under different conditions. In chronic
status, TNF-α may manifest beneficial rather than harmful
effects and there may be a bi-directional regulatory pathway
of TNF-α under different circumstances (Fan et al., 2015).
The increased TNF-α level induced by single administration
of ketamine facilitates neuroinflammation, but conversely,
continuous repetitive stimulation by ketamine decreases TNF-
α level, thereby weakening the neuroprotective effect of TNF-
α and further aggravating the neurotoxicity of ketamine in
the central nervous system. We also directly determined
hippocampal mRNA levels of IL-6, IL-1β, and TNF-α, and most
of results were consistent with the changes of corresponding
protein levels. But to our surprise, the mRNA level of TNF-
α after multiple ketamine administration was still significantly
increased, which was contrary to the changing tendency of
TNF-α protein level. This may be due to the increased
protein degradation of TNF-α, although the exact reason is
unclear.
The underlying molecular mechanism by which ketamine
affects expression of IL-6, IL-1β, and TNF-α needs to be further
explored. Toll-like receptor 4 (TLR4) has been suggested to
be responsible for LPS recognition and subsequent production
of pivotal inflammatory cytokines, such as IL-1β, IL-6, and
TNF-α (Beutler and Rietschel, 2003). It has been shown that
ketamine produces a proinflammatory effect by increasing
TLR4 expression in a NMDA-independent manner. In a
recent study, TLR4 was silenced with TLR4-siRNA vector and
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FIGURE 7 | Effects of acute and chronic ketamine administration on the mRNA levels of IL-6, IL-1β, and TNF-α in mouse hippocampus. (A–C) The
results of qRT-PCR show that 6 months intraperitoneal injection of ketamine increased the mRNA levels of IL-6 and IL-1β, but decreased the mRNA level of TNF-α.
(D–F) The results of qRT-PCR show that single intraperitoneal injection of ketamine increased the mRNA levels of IL-6, IL-1β, and TNF-α. (G–I) The results of
qRT-PCR show that multiple intraperitoneal injection of ketamine increased the mRNA levels of IL-6, IL-1β, and TNF-α. Data are expressed as mean ± SEM, n = 5
for each group. Statistical analysis used ANOVA to compare the difference between saline-treated group and each ketamine-treated group (∗p < 0.05; ∗∗p < 0.01).
found that after TLR4-siRNA transfection, RAW264.7 cells
pretreated with ketamine no longer promoted IL-6 and TNF-
α expression in the presence of LPS (Meng et al., 2015).
However, the exact mechanism of how ketamine induces dual
function of TNF-α under different conditions still remains to be
determined.
Although, the present study indicates that inflammatory
cytokine levels may be involved in behavioral changes in mice,
there are still limitations. After all, the spatial recognition
memory and emotional response in mice did not strictly
correspond to the alterations in the levels of IL-6, IL-1β, and
TNF-α induced by ketamine, so some other factors must
exist. Moreover, it is still unknown whether the behavioral
performances would change if the expression of these
inflammatory cytokines were silenced. In future studies, we
should focus on the underlying mechanism, exploring the exact
roles of IL-6, IL-1β, and TNF-α in spatial memory deficits and
emotional response.
CONCLUSION
We found that chronic ketamine administration at the dose
of 60 mg/kg (not 30 mg/kg) induced spatial recognition
memory deficit and reduced anxiety-like behaviors in mice.
Moreover, our findings indicate that ketamine can increase the
levels of the inflammatory cytokines IL-6 and IL-1β, which
would lead to neuroinflammation. Interestingly, the effects of
ketamine on the level of TNF-α are inconsistent under different
conditions, depending on the dose and duration. Single ketamine
administration can increase TNF-α level, while sustained and
repetitive stimulation decrease it. These results reveal new
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insights that alterations in the levels of IL-6, IL-1β, and
TNF-α may play an important role in the neurotoxicity of
ketamine.
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